Progress and outlook of inorganic nanoparticles for delivery of nucleic acid sequences related to orthopedic pathologies: A review

Tissue Engineering - Part B: Reviews

Volumn 18, Issue 1, 2012, Pages 1-14

  Wagner, Darcy E ^a   Bhaduri, Sarit B ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING POPULATION; CELL BIOLOGY; CLINICAL MEDICINE; IMMUNE RESPONSE; IMPLANT DEVICES; INORGANIC MATERIALS; INORGANIC NANOPARTICLE; MEDICAL NEEDS; MOLECULAR GENETICS; NONVIRAL; ORTHOPEDIC APPLICATIONS; PARTICLE-BASED METHODS; POSSIBLE FUTURES; TREATMENT DURATION; VIRAL VECTORS;

CYTOLOGY; DISEASES; MOLECULAR BIOLOGY; NANOPARTICLES; NUCLEIC ACID SEQUENCES; PATHOLOGY; POPULATION STATISTICS;

GENE THERAPY;

ADENOVIRUS VECTOR; AMMONIUM MAGNESIUM PHOSPHATE; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 9; DNA; ENHANCED GREEN FLUORESCENT PROTEIN; FIBROBLAST GROWTH FACTOR 1; GOLD NANOPARTICLE; INORGANIC COMPOUND; INOSITOL TRISPHOSPHATE; IRON; LENTIVIRUS VECTOR; MESSENGER RNA; NANOPARTICLE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOGENIC PROTEIN 1; OSTEOPROTEGERIN; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR; RETROVIRUS VECTOR; RNA; SILICON DIOXIDE; SMALL INTERFERING RNA; SOMATOMEDIN B; SOMATOMEDIN C; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; VASCULOTROPIN;

BONE GRAFT; BONE GROWTH; CALCIUM TRANSPORT; DNA SYNTHESIS; DNA TRANSFECTION; ENCHONDRAL OSSIFICATION; FRACTURE; FRACTURE HEALING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; NUCLEAR PORE COMPLEX; NUCLEOTIDE SEQUENCE; ORTHOPEDICS; OSSIFICATION; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; VIRAL GENE DELIVERY SYSTEM;

BASE SEQUENCE; BONE AND BONES; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; INORGANIC CHEMICALS; NANOPARTICLES;

EID: 84856151412     PISSN: 19373368     EISSN: 19373376     Source Type: Journal    
DOI: 10.1089/ten.teb.2011.0081     Document Type: Review

References (193)

1. Bonadio, J., Smiley, E., Patil, P., and Goldstein, S. Localized, direct plasmid genedelivery in vivo: prolonged therapy results in reproducible tissue regeneration. Nat Med 5, 753, 1999.
2. Schmidt-Rohlfing, B., Tzioupis, C., Menzel, C., and Pape, H. Tissue engineering of bone tissue. Principles and clinical applications. Unfallchirurg 112, 785, 2009.
3. Peng, L., Cheng, X., Zhuo, R., Lan, J., Wang, Y., Shi, B., et al. Novel gene-activated matrix with embedded chitosan/plasmidDNAnanoparticles encoding PDGF for periodontal tissue engineering. J Biomed Mat Res A 90A, 564, 2009.
4. Betz, O., Betz, V., Abdulazim, A., Penzkofer, R., Schmitt, B., Schroeder, C., et al. The repair of critical-sized bone defects using expedited, autologous BMP-2 gene-activated fat implants. Tissue Eng Part A 16, 1093, 2010.
5. Orsi, S., Capua, A., Guarnieri, D., Marasco, D., and Netti, P. Cell recruitment and transfection in gene activated collagen matrix. Biomaterials 31, 570, 2010.
6. Carofino, B.C., and Lieberman, J.R. Gene therapy applications for fracture-healing. J Bone Joint Surg Am 90, 99, 2008.
7. Witlox, M.A., Lamfers, M.L., Wuisman, P.I.J.M., Curiel, D.T., and Siegal, G.P. Evolving gene therapy approaches for osteosarcoma using viral vectors: review. Bone 40, 797, 2007.
8. Kofron, M.D., and Laurencin, C.T. Bone tissue engineering by gene delivery. Adv Drug Deliv Rev 58, 555, 2006.
9. Gersbach, C., Phillips, J., and Garcia, A. Genetic engineering for skeletal regenerative medicine. Annu Rev Biomed Eng 9, 87, 2007.
10. Bonadio, J., Goldstein, S.A., and Levy, R.J. Gene therapy for tissue repair and regeneration. Adv Drug Deliv Rev 33, 53, 1998.
11. Franceschi, R.T. Biological approaches to bone regeneration by gene therapy. J Dent Res 84, 1093, 2005.
12. Boden, S. The ABCs of BMPs. Orthop Nurs 24, 49, 2005.
13. Takigami, H., Kumagai, K., Latson, L., Togawa, D., Bauer, T., Powell, K., et al. Bone formation following OP-1 implantation is improved by addition of autogenous bone marrow cells in a canine femur defect model. J Orthop Res 25, 1333, 2007.
14. Deutsch, H. High-dose bone morphogenetic proteininduced ectopic abdomen bone growth. Spine J 10, e1, 2010.
15. Benglis, D., Wang, M.Y., and Levi, A.D. A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Neurosurgery 62, 423, 2008.
16. Vaidya, R., Sethi, A., Bartol, S., Jacobson, M., Coe, C., and Craig, J.G. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions. J Spinal Disord Tech 28, 557, 2008.
17. Wong, D.A., Kumar, A., Jatana, S., Ghiselli, G., and Wong, K. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J 8, 1011, 2008.
18. Fischer, J., Kolk, A., Wolfart, S., Pautke, C., Warnke, P.H., Plank, C., et al. Future of local bone regeneration-protein versus gene therapy. J Craniomaxillofac Surg 39, 54, 2011.
19. Evans, C., Ghivizzani, S., and Robbins, P. Orthopedic gene therapy in 2008. Mol Ther 17, 231, 2009.
20. Luo, D., and Saltzman, W.M. Synthetic DNA delivery systems. Nat Biotechnol 18, 33, 2000.
21. Pouton, C., and Seymour, L. Key issues in non-viral gene delivery. Adv Drug Deliv Rev 34, 3, 1998.
22. Sokolova, V., and Epple, M. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew Chem Int Ed Engl 47, 1382, 2008.
23. Bonadio, J. Tissue engineering via local gene delivery. J Mol Med 78, 303, 2000.
24. Yang, L., and Webster, T. Nanotechnology controlled drug delivery for treating bone diseases. Expert Opin Drug Deliv 6, 851, 2009.
25. Bhattacharya, S., Kudgus, R., Bhattacharya, R., and Mukherjee, P. Inorganic nanoparticles in cancer therapy. Pharm Res 28, 237, 2011.
26. Bonadio, J. Tissue engineering via local gene delivery: update and future prospects for enhancing the technology. Adv Drug Deliv Rev 44, 185, 2000.
27. Lieberman, J., Le, L., Wu, L., Finerman, G., Berk, A., Witte, O., et al. Regional gene therapy with a BMP-2 producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 16, 330, 1998.
28. Kimelman, N., Pelled, G., Helm, G.A., Huard, J., Schwarz, E.M., and Gazit, D. Review: gene-and stem cell-based therapeutics for bone regeneration and repair. Tissue Eng 13, 1135, 2007.
29. Kofron, M.D., and Laurencin, C.T. Orthopaedic applications of gene therapy. Curr Gene Ther 5, 37, 2005.
30. Boden,S.,Barnes,B.,Lous-Ugbo, J.,Tomak,P.,Park,M.S.,Park, J.S., et al. Optimized carrier matrix allows loserdose of rhBMP-2 to achieve spine fusion in non-human primates. Proceedings of the NASS 18th Annual Meeting. Spine J 3, 80S, 2003.
31. Boden, S., Kraiwattanapong, C., Louis-Ugbo, J., Barnes, B., and Hutton, W. Comparison of Healos/bone marrow to INFUSE(rhBMP-2acs) with a collagen-ceramic sponge bulking agent as graft substitutes for lumbar spine fusion. Proceedings of the NASS 19th Annual Meeting. Spine J 4, 24S, 2004.
32. Park, J., Ries, J., Gelse, K., Kloss, F., von der Mark, K., Wiltfang, J., et al. Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther 10, 1089, 2003.
33. Ishihara, A., Shields, K., Litsky, A., Mattoon, J., Weisbrode, S., Bartlett, J., et al. Osteogenic gene regulation and relative acceleration of healing by adenoviral-mediated transfer of human BMP-2 or-6 in equine osteotomy and ostectomy models. J Orthop Res 26, 764, 2008.
34. Lieberman, J., Daluiski, A., Stevenson S., Wu, L., McAllister, P., Lee, Y.P., et al. The effect of regional gene therapy with bone morphogenetic protein-2-producing bonemarrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 81, 905, 1999.
35. Koh, J., Zhao, Z., Wang, Z., Lewis, I.S., Krebsbach, P.H., and Franceschi, R.T. Combinatorial gene therapy with BMP2/7 enhances cranial bone regeneration. J Dent Res 87, 845, 2008.
36. Zhu, W., Rawlins, B., Boachie-Adjei, O., Myers, E., Arimizu, J., Choi, E., et al. Combined bone morphogenetic protein-2 and-7 enhances osteoblastic differentiation and spine fusion in a rodent model. J Bone Miner Res 19, 2021, 2004.
37. Nakase, T., Nomura, S., Yoshikawa, H., Hashimoto, J., Hirota, S., Kitamura, Y., et al. Transient and localized expression of bone morphogenetic protein 4 messenger RNA during fracture healing. J Bone Miner Res 9, 651, 1994.
38. Shen, H., Peng, H., Usas, A., Gearhart, B., Fu, F., and Huard, J. Structural and functional healing of critical-size segmental bone defects by trasduced muscle-derived cells expressing BMP4. J Gene Med 6, 984, 2004.
39. Peng, H., Wright, V., Usas, A., Gearhart, B., Shen, H., Cummins, J., et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110, 751, 2002.
40. Rundle, C., Strong, D., Chen, S., Linkhart, T., Sheng, M., Wergedal, J., et al. Retroviral-based gene therapy with cyclooxygenase-2 promotes the union of bony callus tissues and accelerates fracture healing in the rat. J Gene Med 10, 229, 2008.
41. Rundle, C., Miyakoshi, N., Kasukawa, Y., Chen, S., Sheng, M., Wergedal, J., et al. In vivo bone formation in fracture repair induced by direct retroviral-based gene therapy with bone morphogenetic protein-4. Bone 32, 591, 2003.
42. Huang, Y., Simmons, C., Kaigler, D., Rice, K., and Mooney, D. Bone regeneration in a rat cranial defect with delivery of PEI-condensed plasmid DNA encoding for bone morphogenetic protein-4 (BMP-4). Gene Ther 12, 418, 2005.
43. Li, B.C., Zhang, J.J., Xu, C., Zhang, J.Y., and Zhao, H. Treatment of rabbit femoral defect by firearm with BMP-4 gene combined with TGF-beta1. J Trauma 66, 450, 2009.
44. Fang, J., Zhu, Y.Y., Smiley, E., Bonadio, J., Rouleau, J.P., Goldstein, S.A., et al. Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc Natl Acad Sci USA 93, 5753, 1996.
45. Bertone, A., Pittman, D., Bouxsein, M., Li, J., Clancy, B., and Seeherman, H. Adenoviral-mediated transfer of human BMP-6 gene accelerates healing in a rabbit ulnar osteotomy model. J Orthop Res 22, 1261, 2004.
46. Breitbart, A.S., Grande, D.A., Mason, J.M., Barcia, M., James, T., and Grant, R.T. Gene-enhanced tissue engineering: applications for bone healing using cultured periosteal cells transduced retrovirally with the BMP-7 gene. Ann Plast Surg 42, 488, 1999.
47. Hidaka, C., Goshi, K., Rawlins, B., Boachie-Adjei, O., and Crystal, R. Enhancement of spine fusion using combined gene therapy and tissue engineering BMP-7 expressing bone marrow cells and allograft bone. Spine 28, 2049, 2003.
48. Li, J., Hankins, G., Kao, C., Li, H., Kammauff, J., and Helm, G. Osteogenesis in rats induced by a novel recombinant helper-dependent bone morphogenetic protein-9 (BMP-9) adenovirus. J Gene Med 5, 748, 2003.
49. Helm, G.A., Alden, T.D., Beres, E.J., Hudson, S.B., Das, S., Engh, J.A., et al. Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. J Neurosurg 92, 191, 2000.
50. Varaday, P., Li, J., Cunningham, M., Beres, M., Das, S., Engh, J., et al. Morphologic analysis of BMP-9 gene therapyinduced osteogenesis. Hum Gene Ther 12, 697, 2001.
51. Kato, T., Kawaguchi, H., Hanada, K., Aoyama, I., Hiyama, Y., Nakamura, T., et al. Single local injection of recombinant fibroblast growth factor-2 stimulates healing of segmental bone defects in rabbits. J Orthop Res 16, 654, 1998.
52. Nakamura, T., Hara, Y., Tagawa, M., Tamura, M., Yuge, T., and Fukuda, H. Recombinant human fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture. J Bone Miner Res 13, 942, 1998.
53. Ornitz, D., and Marie, P. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Gene Dev 16, 1446, 2002.
54. Guo, X., Zheng, Q., Kulbatski, I., Yuan, Q., Yang, S., Shao, Z., et al. Bone regeneration with active angiogenesis by basic fibroblast growth factor gene transfected mesenchymal stem cells seeded on porous beta-TCP ceramic scaffolds. Biomed Mater 1, 93, 2006.
55. Shen, F.H., Visger, J.M., Balian, G., Hurwitz, S.R., and Diduch, D.R. Systematically administered mesenchymal stromal cells transduced with insulin-like growth factor-I localize to a fracture site and potentiate healing. J Orthop Trauma 16, 651, 2002.
56. Chang, P.C., Cirelli, J.A., Jin, Q., Seol, Y.J., Sugai, J.V., D'Silva, N.J., et al. Adenovirus encoding human plateletderived growth factor-B delivered to alveolar bone defects exhibits safety and biodistribution profiles favorable for clinical use. Hum Gene Ther 20, 486, 2009.
57. Hock, J., Canalis, E., and Centrella, M. Transforming growth factor-beta stimulates bone matrix apposition and bone cell replication in cultured fetal rat carvariae. Endocrinology 126, 421, 1990.
58. Joyce, M., Roberts, A., Sporn, M., and Bolander, M. Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol 110, 2195, 1990.
59. Gerber, H., Vu, T., Ryan, A., Kowalski, J., Werb, Z., and Ferrara, N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5, 623, 1999.
60. Street, J., Bao, M., deGuzman, L., Bunting, S., Peale, F., Ferrara, N., et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 99, 9656, 2002.
61. Keramaris, N., Calori, N., Nikolaou, V., Schemitsch, E., and Giannoudis, P. Fracture vascularity and bone healing: a systematic review of the role of VEGF. Injury 39, S45, 2008.
62. Ito, H., Koefoed, M., Tiyapatanaputi, P., Gromov, K., Goater, J.J., Carmouche, J., et al. Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med 11, 291, 2005.
63. Li, R., Stewart, D., von Schroeder, H., Mackinnon, E., and Schemitsch, E. Effect of cell-based VEGF gene therapy on healing of a segmental bone defect. J Orthop Res 27, 8, 2009.
64. Geiger, F., Bertram, H., Berger, I., Lorenz, H., Wall, O., Eckhardt, C., et al. Vascular endothelial growth factor gene activated-matrix (VEGF165-GAM) enhances osteogenesis and angiogenesis in large segmental bone defects. J Bone Miner Res 20, 2028, 2005.
65. Tarkka, T., Sipola, A., Jamsa, T., Soini, Y., Yla-Herttuala, S., Tuukkanen, J., et al. Adenoviral VEGF-A gene transfer induces angiogenesis and promotes bone formation in healing osseous tissues. J Gene Med 5, 560, 2003.
66. Boden, S., Liu, Y., Hair, G., Helms, J., Hu, D., and Racine, M. LMP-1, a LIM-domain protein, mediates BMP-6 effects on bone formation. Endocrinology 139, 5125, 1998.
67. Boden, S., Titus, L., Hair, G., Liu, Y., Viggeswarapu, M., Nanes, M., et al. Lumbar spine fusion by local gene therapy with a cDNA encoding a novel osteoinductive protein (LMP-1). Spine 23, 2486, 1998.
68. Lattanzi, W., Parrilla, C., Retoni, A., Logroscino, G., Straface, G., Pecorini, G., et al. Ex vivo-transduced autologous skin fibroblasts expressing human Lim mineralization protein-3 efficiently form new bone in animal models. Gene Ther 15, 1220, 2008.
69. Viggeswarapu, M., Boden, S., Liu, Y., Hair, G., Louis-Ugbo, J., Murakami, H., et al. Adenoviral delivery of LIM mineralization protein-1 induces new-bone formation in vitro and in vivo. J Bone Joint Surg Am 83A, 364, 2001.
70. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S., Yano, K., Fujise, N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329, 1998.
71. Aubin, J.E., and Bonnelye, E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 11, 905, 2000.
72. Chen, R., Kanzaki, H., Chiba, M., Nishimura, M., Kanzaki, R., and Igarashi, K. Local osteoprotegerin gene transfer to periodontal tissue inhibits liopopolysaccharaide-induced alveolar bone resportion. J Periodontal Res 43, 237, 2008.
73. Bolon, B., Carter, C., Daris, M., Morony, S., Capparelli, C., Hsieh, A., et al. Adenoviral delivery of osteoprotegerin ameloriates bone resorption in a mouse ovariectomy model of osteoporosis. Mol Ther 3, 197, 2001.
74. Kostenuik, P. Osteoprotegerin and RANKL regulate bone resporptoin, density, geometry and strength. Curr Opin Pharmacol 5, 618, 2005.
75. Kanzaki, H., Chiba, M., Arai, K., Takahashi, I., Haryuama, N., Nishimura, M., et al. Local RANKL gene transfer to the periodontal tissue accelerates orthodontic tooth movement. Gene Ther 13, 678, 2006.
76. Lee, K., Kim, H., Li, Q., Chi, X., Ueta, C., Komori, T., et al. Runx2 is a common target of transforming growth factor b1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblasts-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 20, 8783, 2000.
77. Zhao, Z., Wang, Z., Ge, C., Krebsbach, P., and Franceschi, R.T. Healing cranial defects with AdRunx2-transduced marrow stromal cells. J Dent Res 86, 1207, 2007.
78. Byers, B., Guldberg, R., Hutmacher, D., and Garcia, A. Effects of Runx2 genetic engineering and in vitro maturation of tissue-engineered constructs on the repair of critical size bone defects. J Biomed Mat Res A 76A, 646, 2006.
79. Phillips, J., Guldberg, R., and Garcia, A. Dermal fibroblasts genetically modified to express Runx2/Cbfa1 as a mineralizing cell source for bone tissue engineering. Tissue Eng 13, 2029, 2007.
80. Phillips, J., Hutmacher, D., Guldberg, R., and Garcia, A. Mineralization capacity of Runx2/Cfab1-genetically engineered fibroblasts is scaffold dependent. Biomaterials 27, 5535, 2006.
81. Sangadala, S., Boden, S., Viggeswarapu, M., Liu, Y., and Titus, L. LIM mineralization protein-1 potentiates bone morphogenetic protein responsiveness via a novel interaction with Smurf1 resulting in decreased ubiquitination of Smads. J Biol Chem 281, 17212, 2006.
82. Escoffre, J., Teissie, T., and Rols, M. Gene transfer: how can the biological barriers be overcome? J Membr Biol 236, 61, 2010.
83. Anwer, K. Formulations for DNA delivery via electroporation in vivo. Methods Mol Biol 423, 77, 2008.
84. Liu, F., Song, Y., and Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6, 1258, 1999.
85. Thomas, C., Ehrhardt, A., and Kay, M. Progress and problems associated with the use of viral vectors for gene therapy. Nat Rev Genet 45, 346, 2003.
86. Glover, D., Lipps, H., and Jans, D. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 6, 299, 2005.
87. Raper, S.E., Chirmule, N., Lee, F.S., Wivel, N.A., Bagg, A., Gao, G.P., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80, 148, 2003.
88. Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. New Engl J Med 348, 255, 2003.
89. Evans, C.H., Ghivizzani, S.C., and Robbins, P.D. Arthritis gene therapy's first death. Arthritis Res Ther 10, 110, 2008.
90. Maryuama, A., Ishihara, T., Kim, J., Kim, S., and Akaike, T. Design of multi-layered nanoparticles as a DNA carrier. Colloids Surface A 153, 439, 1999.
91. Panyam, J., and Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55, 329, 2003.
92. Hwang, S., and Davis, M. Cationic polymers for gene delivery: designs for overcoming barriers to systemic administration. Curr Opin Mol Ther 3, 183, 2001.
93. Dang, J., and Leong, K. Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv Rev 58, 487, 2006.
94. Ratner, B., and Bryant, S. Biomaterials: where we have been and where we are going. Annu Rev Biomed Eng 6, 41, 2004.
95. Wang, J., Lee, I., Lim, W., Chia, S., Yu, H., Leong, K., et al. Evaluation of collagen and methylated collagen as gene carriers. Int J Pharm 279, 115, 2004.
96. DiMartino, A., Sittinger, M., and Risbud, M. Chitosan: a versatile biopolymer for orthopaedic tissue-engineering. Biomaterials 26, 5983, 2005.
97. Chowdhury, E.H., and Akaike, T. Bio-functional inorganic materials: an attractive branch of gene-based nano-medicine delivery for 21st century. Curr Gene Ther 5, 669, 2005.
98. Kawano, T., Yamagata, M., Takahashi, H., Niidome, Y., Yamada, S., Katayama, Y., et al. Stabilizing of plasmid DNA in vivo by PEG-modified cationic gold nanoparticles and the gene expression assisted with electrical pulses. J Control Release 111, 382, 2006.
99. Kim, T., Feng, Q., Kim, J., Wu, J., Wang, H., Chen, G., et al. Antimicrobial effects of metal ions (Ag+, Cu2+, Zn2+) in hydroxyapatite. J Mater Sci Mater M 9, 129, 1998.
100. Nair, L., and Laurencin, C. Nanofibers and nanoparticles for orthopaedic surgery applications. J Bone Joint Surg Am 90, 128, 2008.
101. Shen, H., Tan, J., and Saltzman, W.M. Surface-mediated gene transfer from nanocomposites of controlled texture. Nat Mater 3, 569, 2004.
102. Kneuer, C., Sameti, M., Haltner, E.G., Schiestel, T., Schirra, H., Schmidt, H., et al. Silica nanoparticles modified with aminosilanes as carriers for plasmid DNA. Int J Pharm 196, 257, 2000.
103. Luo, D., and Saltzman, W.M. Enhancement of transfection by physical concentration of DNA at the cell surface. Nat Biotechnol 18, 893, 2000.
104. Kumar, M., Sameti, M., Mohapatra, S., Kong, X., Lockey, R., Bakowsky, U., et al. Cationic silica nanoparticles as gene carriers: synthesis, characterization and transfection efficiency in vitro and in vivo. J Nanosci Nanotechnol 4, 876, 2004.
105. Lewis, D., Hagstrom, J., Loomis, A., Wolff, J., and Herweijer, H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 32, 107, 2002.
106. Uchida, M., Li, X., Mertens, P., and Alpar, H. Transfection by particle bombardment: delivery of plasmid DNA into mammalian cells using gene gun. Biochim Biophys Acta 1790, 754, 2009.
107. Chang, M., Chen, J., Yeh, C., Chang, M., Liang, C., Chiu, C., et al. Gene gun bombardment with DNA-coated gold particles is a potential alternative to hydrodynamics-based transfection for delivering genes into superficial hepatocytes. Hum Gene Ther 19, 391, 2008.
108. Sapet, C., LeGourrierec, L., Schillinger, U., Mykhaylyk, O., Augier, S., Plank, C., et al. Magnetofection: magnetically assisted & targeted nucleic acids delivery. Drug Deliv Technol 10, 24, 2010.
109. Maurisse, R., De Semir, D., Emamekhoo, H., Bedaya, B., Abdolmohammadi, A., Parsi, H., et al. Comparative transfection of DNA into primary and transformed mammalian cells from different lineages. BMC Biotechnol 10, 9, 2010.
110. Ivorra, A., Al-Sakere, B., Rubinsky, B., and Mir, L. In vivo electrical conductivity measurements during and after tumor electroporation: conductivity changes reflect the treatment outcome. Phys Med Biol 54, 5949, 2009.
111. Mintzer, M., and Simanek, E. Nonviral vectors for gene delivery. Chem Rev 109, 259, 2009.
112. Xu, Z., Zeng, Q., Lu, G., and Yu, A. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Sci 61, 1027, 2006.
113. Son, S., Bai, X., and Lee, S. Inorganic hollow nanoparticles and nanotubes in nanomedicine: part 1. Drug/gene delivery applications. Drug Discov Today 12, 650, 2007.
114. Luo, D., Han, E., Belcheva, N., and Saltzman, W.M. A selfassembled, modular DNA delivery system mediated by silica nanoparticles. J Control Release 95, 333, 2004.
115. Bhakta, G., Mitra, S., and Maitra, A. DNA encapsulated magnesium and manganous phosphate nanoparticles: potential non-viral vectors for gene delivery. Biomaterials 26, 2157, 2005.
116. Sokolova, V., Radtke, I., Heumann, R., and Epple, M. Effective transfection of cells with multi-shell calcium phosphate-DNA nanoparticles. Biomaterials 27, 3147, 2006.
117. Yamamoto, A., Kormann, M., Rosenecker, J., and Rudolph, C. Current prospects for mRNA gene delivery. Eur J Pharm Biopharm 71, 484, 2009.
118. Bonetta, L. RNA-based therapeutics: ready for delivery? Cell 136, 581, 2009.
119. Takahashi, Y., Nishikawa, M., and Takakura, Y. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAibased gene therapy. Adv Drug Deliv Rev 61, 760, 2009.
120. Qiu, P., Ziegelhoffer, P., Sun, J., and Yang, N.S. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther 3, 262, 1996.
121. Whitehead, K., Langer, R., and Anderson, D. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8, 129, 2009.
122. Mei, J., Gao, Y., Zhang, L., Cai, X., Qian, Z., Huang, H., et al. VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro. Exp Oncol 30, 29, 2008.
123. Schaffert, D., and Wagner, E. Gene therapy progress and prospects: synthetic polymer-based systems. Gene Ther 15, 1131, 2008.
124. Tavernier, G., Andries, O., Demeester, J., Sanders, N., DeSmedt, S., and Rejman, J. mRNA as gene therapeutic: how to control protein expression. J Control Release 150, 238, 2011.
125. Li, S., and Huang, L. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr Opin Investig Drugs 9, 1317, 2008.
126. Tokatlian, T., and Segura, T. siRNA applications in nanomedicine. WIRESs Nanomed Nanobiotechnol 2, 305, 2010.
127. Schreier, H. The new frontier: gene and oligonucleotide therapy. Pharm Acta Helv 68, 145, 1994.
128. Donze, O., and Picard, D. RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res 30, e46, 2002.
129. Sazani, P., Astriab-Fischer, A., and Kole, R. Effects of base modifications on antisense properties of 2'-o-methoxyethyl and PNA oligonucleotides. Antisense Nucleic Acid Drug Dev A 13, 119, 2003.
130. Sokolova, V., Kovtun, A., Prymak, O., Meyer-Zaika, W., Kubareva, E.A., Romanova, E.A., et al. Functionalisation of calcium phosphate nanoparticles by oligonucleotides and their application for gene silencing. J Mater Chem 17, 721, 2007.
131. Gary, D., Puri, N., and Won, Y. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 121, 64, 2007.
132. Haupenthal, J., Baehr, C., Kiermayer, S., Zeuzem, S., and Piiper, A. Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem Pharmacol 71, 702, 2006.
133. Malone, R.W., Felgner, P.L., and Verma, I.M. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA 86, 6077, 1989.
134. Erbacher, P., Roche, A.C., Monsigny, M., and Midoux, P. Putative role of chloroquine in gene transfer into a human hepatoma cell line by DNA lactosylated polylysine complexes. Exp Cell Res 225, 186, 1996.
135. Goldberg, M., Langer, R., and Xinqiao, J. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed 18, 241, 2007.
136. Caminade, A.M., Turrin, C.O., and Majoral, J.P. Dendrimers and DNA: combinations of two special topologies for nanomaterials and biology. Chemistry 14, 7422, 2008.
137. Martino, S., Girolamo, I., Tiribuzi, R., D'Angelo, F., Datti, A., and Orlacchio, A. Efficient siRNA delivery by the cationic liposome DOTAP in human hematopoietic stem cells differentiating into dendritic cells. J Biomed Biotechnol 2009, 410260, 2009.
138. Cherng, J.Y., Talsma, H., Verrijk, R., Crommelin, D.J.A., and Hennink, W.E. The effect of formulation parameters on the size of poly-((2-dimethylamino) ethyl methacrylate)-plasmid complexes. Eur J Pharm Biopharm 473, 2919, 1999.
139. Kossovsky, N., Hnatyszyn, J.H., and Gelman, A. Targeted transfection nanoparticles. U.S. Patent No. 5460831, 1995.
140. Maitra, A. Calcium phosphate nanoparticles: secondgeneration nonviral vectors in gene therapy. Expert Rev Mol Diagn 5, 893, 2005.
141. Chowdhury, E.H., Maruyama, A., Kano, A., Nagaoka, M., Kotaka, M., Hirose, S., et al. pH-sensing nano-crystals of carbonate apatite: effects on intracellular delivery and release of DNA for efficient expression into mammalian cells. Gene 376, 87, 2006.
142. Nabiev, I., Mitchell, S., Davies, A., Williams, Y., Kelleher, D., Moore, R., et al. Nonfunctionalized nanocrystals can exploit a cell's active transport machinery delivering them to specific nuclear and cytoplasmic compartments. Nano Lett 7, 3452, 2007.
143. van der Aa, M.A.E.M., Mastrobattista, E., Oosting, R.S., Hennink, W.E., Koning, G.A., and Crommelin, D.J.A. The nuclear pore complex: the gateway to successful nonviral gene delivery. Pharm Res 23, 447, 2006.
144. Pouton, C.W., Wagstaff, K.M., Roth, D.M., Moseley, G.W., and Jans, D.A. Targeted delivery to the nucleus. Adv Drug Deliv Rev 59, 698, 2007.
145. Dean, D.A., Strong, D.D., and Zimmer, W.E. Nuclear entry of nonviral vectors. Gene Ther 12, 881, 2005.
146. Yang, W., and Musser, S. Visualizing single molecules interacting with nuclear pore complexes by narrow-field epifluorescence microscopy. Methods 39, 316, 2006.
147. Gupta, B., Levchenko, T., and Torchilin, V. Intracellular deliveryof largemoleculesandsmallparticles bycell-penetrating proteins and peptides. Adv Drug Deliv Rev 57, 637, 2005.
148. Lee, M.A., Dunn, R.C., Clapham, D.E., and Stehno-Bittel, L. Calcium regulation of nuclear pore permeability. Cell Calcium 23, 91, 1998.
149. Soldati, T., and Schliwa, M. Powering membrane traffic in endocytosis and recycling. Nature 7, 897, 2006.
150. Raemdonck, K., Vandenbroucke, R., Demeester, D., Sanders, N., and Smedt, S. Maintaining the silence: reflections on long-term RNAi. Drug Discov Today 13, 917, 2008.
151. Yamada, Y., Nomura, T., Harashima, H., Yamashita, A., Katoono, R., and Yui, N. Intranuclear DNA release is a determinant of transfection activity for a non-viral vector: biocleavable polyrotaxane as a supramolecularly dissociative condenser for efficient intranuclear DNA release. Biol Pharm Bull 33, 1218, 2010.
152. Trentin, D., Hubbell, J., and Hall, H. Non-viral gene delivery for local and controlled DNA release. J Control Release 102, 263, 2005.
153. Evans, C. Gene therapy for the regeneration of bone. Injury 42, 599, 2011.
154. Anitua, E., Sanchez, M., Orive, G., and Andia, I. Delivering growth factors for therapeutics. Trends Pharmacol 29, 37, 2008.
155. Hollinger, J.O., Winn, S., and Bonadio, J. Options for tissue engineering to address challenges of the aging skeleton. Tissue Eng 6, 341, 2000.
156. Mykhaylyk, O., Vlaskou, D., Tresilwised, N., Pithayanukul, P., Moeller, W., and Plank, C. Magnetic nanoparticle formulations for DNA and siRNA delivery. J Magn Magn Mater 311, 275, 2007.
157. Namgung, R., Singha, K., Yu, M.K., John, S., Kim, Y.S., Ahn, Y., et al. Hybrid superparamagnetic iron oxide nanoparticle-branched polthylenimin magnetoplexes for gene transfection of vascular endothelial cells. Biomaterials 31, 4202, 2010.
158. Smith, C., Fuente, J., Pelaz, B., Furlani, E., Mullin, M., and Berry, C. The effect of static magnetic fields and tat peptides on cellular and nuclear uptake of magnetic nanoparticles. Biomaterials 31, 4392, 2010.
159. Yiu, H., McBain, S., Lethbridge, Z., Lees, M., and Dobson, J. Preparation and characterization of polyethyleniminecoated Fe3O4-MCM-48 nanocomposite particles as a novel agent for magnet-assisted transfection. J Biomed Mater Res A 92, 386, 2010.
160. Jeffrey, N., McBain, S., Dobson, J., and Chari, D. Uptake of systemically administered magnetic nanoparticles (MNPs) in areas of experimental spinal cord injury (SCI). J Tissue Eng Regen Med 3, 153, 2009.
161. McBain, S.C., Yiu, H.H.P., and Dobson, J. Magnetic nanoparticles for gene and drug delivery. Int J Nanomed 3, 169, 2008.
162. Medarova, Z., Kumar, M., Ng, S.W., Yang, J., Barteneva, N., Evgenov, N.V., Petkova, V., and Moore, A. Multifunctional magnetic nanocarrieres for image-tagged siRNA delivery to intact pancreatic islets. Transplantation 86, 1170, 2008.
163. Mykhaylyk, O., Zelphati, O., Rosenecker, J., and Plank, C. siRNA delivery by magnetofection. Curr Opin Mol Ther 10, 493, 2008.
164. Yang, S., Sun, J., Tsuang, Y., Chen, L., Hong, C., Yang, H., and Horng, H. Ex vivo magnetofection with magnetic nanoparticles: a novel platform for nonviral tissue engineering. Artif Organs 32, 195, 2007.
165. Gupta, A., and Gupta, M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26, 3995, 2005.
166. Kneuer, C., Sameti, M., Bakowsky, U., Schiestel, T., Schirra, H., Schmidt, H., et al. A nonviral DNA delivery system based on surface modified silica-nanoparticles can efficiently transfect cells in vitro. Bioconjug Chem 11, 926, 2000.
167. Chen, Y., Xue, Z., Zheng, D., Xia, K., Zhao, Y., Long, Z., et al. Sodium chloride modified silica nanoparticles as a non-viral vector with a high efficiency of DNA transfer into cells. Curr Gene Ther 3, 273, 2003.
168. Moudgil, S., and Ying, J. Calcium-doped organosilicate nanoparticles as gene delivery vehicles for bone cells. Adv Mater 19, 3130, 2007.
169. Roy, I., Mitra, S., Maitra, A., and Mozumdar, S. Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery. Int J Pharm 250, 25, 2003.
170. Choo, H., Cutler, E., and Shon, Y.S. Synthesis of mixed monolayer-protected gold clusters from thiol mictures, variation in the tail group, chain length and solvent. Langmuir 19, 8555, 2003.
171. Larregina, A.T., Watkins, S.C., Erdos, G., Spencer, L.A., Storkus, W.J., Beer, S.D., et al. Direct transfection and activiation of human cutaneous dendritic cells. Gene Ther 8, 608, 2001.
172. Muangmoonchai, R., Wong, S.C., Smirlis, D., Phillips, I.R., and Shardl, E.A. Transfection of liver in vivo by biolistic particle delivery: its use in the investigation of cytochrome P450 gene regulation. Mol Biotechnol 22, 145, 2002.
173. Yang, N.S., and Sun, W.H. Gene gun and other non-viral approaches for cancer gene-therapy. Nat Med 1, 481, 1995.
174. Sandhu, K.K., McIntosh, C.M., Simard, J.M., Smith, S.W., and Rotello, V.M. Gold nanoparticle-mediated transfection of mammalian cells. Bioconjug Chem 13, 3, 2002.
175. Thomas, M., and Klibanov, A. Conjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells. Proc Natl Acad Sci USA 100, 9138, 2003.
176. Rosi, N., Giljohann, D., Thaxton, C., Lytton-Jean, A., Han, M., and Mirkin, C. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 312, 1027, 2007.
177. Huang, X., Qian, W., El-Sayed, I.H., and El-Sayed, M.A. The potential use of the enhanced nonlinear properties of gold nanospheres in photothermal cancer therapy. Lasers Surg Med 39, 747, 2007.
178. Ghosh, P., Han, G., De, M., Kim, C.K., and Rotello, V. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 60, 1307, 2008.
179. Ragusa, A., Garcia, I., and Penades, S. Nanoparticles as nonviral gene delivery vectors. IEEE Trans Nanobioscience 6, 319, 2007.
180. Bonoiu, A., Mahajan, S., Ye, L., Kumar, R., Ding, H., Yong, K.T., et al. MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res 1282, 142, 2009.
181. Hoshino, A., Manabe, N., Hanada, S., Fujioka, K., Yasuhara, M., Kondo, A., et al. Delivery of gene-expressing fragments using quantum dots. Proc SPIE 7189, 71890V, 2009.
182. Tan, W., Jiang, S., and Zhang, Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 28, 1565, 2007.
183. Jordan, M., Schallhorn, A., and Wurm, F. Transfecting mammalian cells: optimization of criticial parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res 24, 596, 1996.
184. Pedraza, C.E., Bassett, D., McKee, M., Nelea, V., Gbureck, U., and Barralet, J. The importance of particle size and DNA condensation salt for calcium phosphate nanoparticle transfection. Biomaterials 29, 3384, 2008.
185. Kuroda, S., Kondo, H., Ohya, K., and Kasugai, S. A new technique with calcium phosphate precipitate enhances efficiency of in vivo plasmid DNA gene transfer. J Pharmacol Sci 97, 227, 2005.
186. Batard, P., Jordan, M., and Wurm, F. Transfer of high copy number plasmid into mammalian cells by calcium phosphate transfection. Gene 270, 61, 2001.
187. Sokolova, V., Kovtun, A., Heumann, R., and Epple, M. Tracking the pathway of calcium phosphate/DNA nanoparticles during cell transfection by incorportation of redfluorescing tetramethylrhodamine isothiocyanate-bovine serum albumin into these nanoparticles. J Biol Inorg Chem 12, 174, 2007.
188. Bisht, S., Bhakta, G., Mitra, S., and Maitra, A. pDNA loaded calcium phosphate nanoparticles: highly efficient non-viral vector for gene delivery. Int J Pharm 288, 157, 2005.
189. Sokolova, V., Prymak, O., Meyer-Zaika, W., Coelfen, H., Rehage, H., Shukla, A., et al. Synthesis and characterization of DNA-functionalized calcium phosphate nanoparticles. Mat Wiss U Werksofftech 37, 441, 2006.
190. Singh, R., Saxena, A., and Mozumdar, S. Calcium phosphate-DNA nanocomposites: morphological studies and their bile duct infusion for liver-direced gene therapy. Int J Appl Ceram Tec 51, 1, 2008.
191. Neumann, S., Kovtun, A., Dietzel, I., Epple, M., and Heumann, R. The use of size-defined DNA-functionalized calcium phosphate nanoparticles to minimize intracellular calcium disturbance during transfection. Biomaterials 30, 6794, 2009.
192. Welzel, T., Radtke, I., Meyer-Zaika, W., Heumann, R., and Epple, M. Transfection of cells with custom-made calcium phosphate nanoparticles coated with DNA. J Mater Chem 14, 2213, 2004.
193. Gonzalez-McQuire, R., Green, D., Partridge, K., Oreffo, R., Mann, S., and Davis, S. Coating of human mesenchymal cells in 3D culture with bioinorganic nanoparticles promotes osteoblastic differentiation and gene transfection. Adv Mater 19, 2236, 2007.